Article
Macrophage Activation Syndrome (MAS) is a hyperinflammatory condition that has a significant mortality risk and may arise in patients with rheumatic disease.
All News
Article
Drug survival may be the best measure of efficacy and safety. A study of novel therapy durability (survival) in patients with RA, axial spondyloarthritis, PsA, and psoriasis shows that while all these drugs are approved for said conditions, drug survival varies by condition, suggesting an ongoing need for individualized treatment.
Article
A study in the Annals of Internal Medicine reports chronic kidney disease (CKD) patients can be safely treated with allopurinol without an increased risk of mortality.
Article
This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.
Dr. John Cush
Tweet
Single center comparison of MAS (n 18) to malignancy related mHLH (n = 16). Notable differences seen in platelet (lower in mHLH 29k v 50K), soluble IL-2R (6814 vs 27972), but more hepatomegaly (25% v 0). Less mortality with MAS (22 v 44%, p 0.18) https://t.co/gYdRfxDM2c https://t.co/ekMJfnzElC
Dr. John Cush
Tweet
Getting Real on PMR
Dr. David Liew talks polymyalgia rheumatica and how our understanding has evolved over the years. #EULAR2022
https://t.co/DyVCxDVPE7 https://t.co/PF7zqxX7yk
Dr. John Cush
Tweet
IL-18, Iike IL-1, is a produced by activation of the inflammasome. IL-18 is a potential bioimarker for #AOSD, closely linked to Dz activity & could be a Tx target, either as IL-18 binding protein (Tadekinig alfa) or mAb against IL-18 (phase 1b) https://t.co/ex231f27rg https://t.co/tjsra4blBi
Dr. John Cush
Tweet
Babies! Safety and Outcomes Data on Pregnancies
#EULAR2022 highlighted several posters on pregnancy, an important subject as most rheumatic diseases afflicts women during their childbearing years. I wanted to share with you the ones that caught my eye...
https://t.co/piA1zhGyAA https://t.co/Kb68AGZgA1
Dr. John Cush
Tweet
FDG-PET/CTscans were used in 58 for FUO evaluations. Dx was Rheumatic (44.5%), malignancy (34.5%), or infectious (10.3%). Most prevalent Rheum dx was vasculitis (17%), especially LG vessel vasculitis. FDG PET/CT is a useful FUO pts https://t.co/NEZDB20OXN https://t.co/4123Gh2v2Y
Dr. John Cush
Tweet
Polymyalgia rheumatica immunological puzzle further illustrated
Infiltrating macrophages expressing IL-6 and GM-CSF may drive the subacromial bursitis often seen in polymyalgia rheumatica, according to new research presented at #EULAR2022.
https://t.co/oa619uNgnB https://t.co/gyNnsMDXGo
Dr. John Cush
Tweet
It's not a museum. It's the new, look, all electronic poster sessions. Rows & rows of 42 inch touch screen monitors on the wall. You can interact with these online monitors, but I was unable to connect to Netflix. https://t.co/0lcYkjFj3D
Dr. John Cush
Tweet
Watch: AURORA-2 Two-year Results Voclosporin For Lupus Nephritis
https://t.co/UisuOOABxG
#EULAR2022 https://t.co/Og8opUJO2h
Dr. John Cush
Tweet
Voclosporin in lupus nephritis - good 3 year continuation data. #EULAR2022 abtr POS 0186 https://t.co/5EKmvIwTpV https://t.co/nh2bNkSp8G
Dr. John Cush
Tweet
Baricitinib fails in 2 phase 3 lupus trials, BRAVE I & II #EULAR2022 abtr POS 0190 https://t.co/44e5NX4V1V
Dr. John Cush
Tweet
Adults with JIA: It ain’t all child’s play
https://t.co/z3xDjKH2ru https://t.co/9DDGYdpMSr
Dr. John Cush
Tweet
New podcast up—“What Worries You, Masters You”
We review recent news, regulatory and guideline updates from the past week. Studies on MTX use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.
https://t.co/jRaLCQAt9K https://t.co/opa22JqU41
Dr. John Cush
Tweet
Exercise and fibromyalgia? Metanalysis of 18 studies & 1184 pts, comparing aerobic, resistance & stretching. All 3 had large & significant effect on pain (not diff from each other); also improves QOL (possibly depression) https://t.co/RYba99OWCh https://t.co/izpHjeXWCt
Dr. John Cush
Tweet
EMA has approved Secukinumab for the expanded approvals for use in pediatric patients with enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) . Approvals based on the JUNIPERA trial, showing reduced the risk of flare & Dz activity w/ SEC https://t.co/6pWc6nEUd9 https://t.co/gGGyzEEh0u
Dr. John Cush
Tweet
Inferior IL-17 Inhibitor Responses in Psoriatic Women
Pooled data from two large (IXE trials show that male patients had greater clinical responses than did female patients with PsA are largely unexplored. Reasons for this is unexplained.
https://t.co/OAu6gCweDt https://t.co/lsM6hZUwNQ
Dr. John Cush
Tweet
Study of IV CTX (n 13) vs mepolizumab (n 7)(MPZ; IL-5 inhib) in severe eosinophilic granulomatosis polyangiitis. BVAS & EOS# equal at mo 1 & 6, but MPZ had better retention(61 vs 5%) & less AEs (29% vs 54%) https://t.co/7s38a67C1r https://t.co/oXLb1ctoc7
